Melanie Senior
Cost-cutting and sales force reductions grabbed the headlines after Pfizer Inc.’s long-anticipated analysts meeting in January 2007. But CEO Jeffrey...
Pfizer's decision to bypass UK wholesalers and go direct to pharmacies should ultimately give it better control over product discounting. Other manufacturers are watching closely, and not just in the UK.
Melanie Senior
Cost-cutting and sales force reductions grabbed the headlines after Pfizer Inc.’s long-anticipated analysts meeting in January 2007. But CEO Jeffrey...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.